Table 5.

Ongoing phase 3 trials of combination therapy in renal cell carcinoma

Treatment	Trial name	ClinicalTrials.gov No.	Enrollment	Primary endpoint	Status
Nivolumab-cabozantinib vs sunitinib	CheckMate 9ER	NCT03141177	630	PFS	Estimated primary completion date: January 2020
Lenvatinib-everolimus or lenvatinib-pembrolizumab vs sunitinib	CLEAR	NCT02811861	1050	PFS	Estimated primary completion date: April 2020
Nivolumab-ipilimumab followed by nivolumab vs nivolumab-cabozantinib	NCI-2018-03694	NCT03793166	1046	OS	Estimated primary completion date: September 2021
NKTR-214-nivolumab vs sunitinib or cabozantinib	CA045002	NCT03729245	600	ORR	Estimated primary completion date: December 2021
Pazopanib-abexinostat vs pazopanib	XYN-602	NCT03592472	413	PFS	Estimated primary completion date: January 2022
Nivolumab-ipilimumab vs placebo	CheckMate 914	NCT03138512	800	DFS	Estimated primary completion date: September 2022
Nivolumab-ipilimumab vs nivolumab	CA209-8Y8	NCT03873402	418	PFS	Estimated primary completion date: December 2022

DFS: Disease-free survival; ORR: Objective response rate; OS: Overall survival; PD-L1: Programmed cell death-ligand 1; PFS: Progression-free survival.